Recent molecular insights into the genomic alterations driving PCNSL have revealed the involvement of additional target pathways that contribute to PCNSL development and resistance to treatment, including resistance to BTK inhibitors.21, 22. Here, BTK is linked to primary central nervous system lymphoma.